5-iminodoxorubicin

has T/C = 173% in test against mouse leukemia P-388; RN given refers to mono-HCL(8S-cis)-isomer; structure in first source

Also Known As:

5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-12-imino-1-methoxy-, monohydrochloride, (8S-cis)-

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Frank, Nicole E: 2 articles (01/2019 - 12/2016)
2.	Olson, Richard D: 2 articles (01/2019 - 12/2016)
3.	Talley, Todd T: 2 articles (01/2019 - 12/2016)
4.	Walsh, Gerald M: 2 articles (01/2019 - 12/2016)
5.	Agulnik, Mark: 1 article (01/2019)
6.	Klausner, Arthur: 1 article (01/2019)
7.	Milhem, Mohammed M: 1 article (01/2019)
8.	Van Tine, Brian A: 1 article (01/2019)
9.	Cusack, Barry J: 1 article (12/2016)

Related Diseases

1.	Sarcoma (Soft Tissue Sarcoma) 01/01/2019 - "A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma."
2.	Cardiotoxicity 01/01/2019 - "13-Deoxy, 5-iminodoxorubicin (GPX-150) is a doxorubicin (DOX) analog synthesized to reduce the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irreversible, cumulative dose-dependent cardiotoxicity of DOX. " 12/01/2016 - "Purpose A novel doxorubicin (DOX) analog, 13-deoxy, 5-iminodoxorubicin (DIDOX), was synthesized to prevent quinone redox cycling and alcohol metabolite formation, two prevailing hypotheses of anthracycline cardiotoxicity. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Anthracyclines
3.	Reactive Oxygen Species (Oxygen Radicals)
4.	3,4-dihydroxybenzohydroxamic acid
5.	quinone (benzoquinone)